Understanding Emergent Biosolutions Inc (EBS) through its ratios

In the latest session, Emergent Biosolutions Inc (NYSE: EBS) closed at $2.53 down -2.32% from its previous closing price of $2.59. In other words, the price has decreased by -$0.0600 from its previous closing price. On the day, 1088975 shares were traded. EBS stock price reached its highest trading level at $2.7180 during the session, while it also had its lowest trading level at $2.4500.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Ratios:

For a deeper understanding of Emergent Biosolutions Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.54 and its Current Ratio is at 1.04. In the meantime, Its Debt-to-Equity ratio is 1.35 whereas as Long-Term Debt/Eq ratio is at 0.71.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 02 ’23 when Zoon Kathryn C sold 1,830 shares for $8.35 per share. The transaction valued at 15,280 led to the insider holds 49,971 shares of the business.

Zoon Kathryn C sold 1,700 shares of EBS for $14,246 on May 25 ’23. The Director now owns 51,801 shares after completing the transaction at $8.38 per share.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EBS now has a Market Capitalization of 132.07M and an Enterprise Value of 880.57M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.13 while its Price-to-Book (P/B) ratio in mrq is 0.20. Its current Enterprise Value per Revenue stands at 0.86 whereas that against EBITDA is -1.70.

Stock Price History:

The Beta on a monthly basis for EBS is 1.20, which has changed by -74.16% over the last 52 weeks, in comparison to a change of 27.39% over the same period for the S&P500. Over the past 52 weeks, EBS has reached a high of $13.67, while it has fallen to a 52-week low of $1.42. The 50-Day Moving Average of the stock is 2.2698, while the 200-Day Moving Average is calculated to be 3.7290.

Shares Statistics:

For the past three months, EBS has traded an average of 3.09M shares per day and 1.43M over the past ten days. A total of 52.20M shares are outstanding, with a floating share count of 50.07M. Insiders hold about 4.08% of the company’s shares, while institutions hold 78.64% stake in the company. Shares short for EBS as of Mar 15, 2024 were 4.91M with a Short Ratio of 1.59, compared to 11.54M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.41% and a Short% of Float of 15.53%.

Earnings Estimates

There are 1 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.83 for the current quarter, with a high estimate of -$0.83 and a low estimate of -$0.83, while EPS last year was -$3.17. The consensus estimate for the next quarter is -$0.63, with high estimates of -$0.63 and low estimates of -$0.63.

Analysts are recommending an EPS of between -$2 and -$2 for the fiscal current year, implying an average EPS of -$2. EPS for the following year is $3.67, with 1 analysts recommending between $3.67 and $3.67.

Revenue Estimates

A total of 1 analysts have provided revenue estimates for EBS’s current fiscal year. The highest revenue estimate was $1.02B, while the lowest revenue estimate was $1.02B, resulting in an average revenue estimate of $1.02B. In the same quarter a year ago, actual revenue was $1.05B, down -2.30% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $1.13B in the next fiscal year. The high estimate is $1.13B and the low estimate is $1.13B. The average revenue growth estimate for next year is up 9.90% from the average revenue estimate for this year.

Most Popular